Therapeutic strategies for inhibiting oncogenic BRAF signaling.

Abstract excerpt

Mitogen-activated protein kinase (MAPK) activation is a common property of human cancers and is often due to activating mutations in the BRAF and RAS genes. BRAF kinase domain mutations, the vast majority of which are V600E, occur in approximately 8% of human tumors. These mutations are non-overlapping in distribution with RAS mutations and are observed most frequently in melanoma but also in tumors arising in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Neoplasms
• Share to Antineoplastic Agents